Pfizer (PFE) : Nippon Life Insurance Co reduced its stake in Pfizer by 0.32% during the most recent quarter end. The investment management company now holds a total of 1,282,473 shares of Pfizer which is valued at $45,258,472 after selling 4,073 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Pfizer makes up approximately 1.09% of Nippon Life Insurance Co’s portfolio.
Other Hedge Funds, Including , Parkside Financial Bank Trust reduced its stake in PFE by selling 1,974 shares or 6.11% in the most recent quarter. The Hedge Fund company now holds 30,323 shares of PFE which is valued at $1,070,099. Pfizer makes up approx 0.51% of Parkside Financial Bank Trust’s portfolio.Penobscot Investment Management Company reduced its stake in PFE by selling 100 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 87,842 shares of PFE which is valued at $3,240,491. Pfizer makes up approx 1.13% of Penobscot Investment Management Company’s portfolio.Umb Bank N Amo reduced its stake in PFE by selling 88,382 shares or 14.34% in the most recent quarter. The Hedge Fund company now holds 528,158 shares of PFE which is valued at $19,462,622. Pfizer makes up approx 0.80% of Umb Bank N Amo’s portfolio.Curbstone Financial Management Corp reduced its stake in PFE by selling 100 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 57,495 shares of PFE which is valued at $2,076,719. Pfizer makes up approx 0.69% of Curbstone Financial Management Corp’s portfolio.
Pfizer closed down -0.51 points or -1.44% at $34.93 with 3,05,40,494 shares getting traded on Monday. Post opening the session at $35.28, the shares hit an intraday low of $34.71 and an intraday high of $35.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.